Latest News

Quotient Clinical announces second US acquisition: QS Pharma

Addition of contract development and manufacturing organisation increases scale of business and adds high potency molecule capability Follows recent acquisition of SeaView Research, the specialist clinical pharmacology business, to further extend US presence   Nottingham, UK, 14 February 2017 Quotient Clinical (“Quotient”), the early phase drug development services provider, today announces that it has acquired […]

Read more..

Quotient Clinical expands into USA through acquisition of SeaView Research, the specialist clinical pharmacology business

Nottingham, UK, 06 February 2017 Quotient Clinical (“Quotient”), the early phase drug development services provider, today announces that it has acquired SeaView Research (“SeaView”), expanding its operations into the USA. The acquisition combines Quotient and SeaView’s complementary customer portfolios, and strengthens the early phase clinical experience of the combined business, enabling the company to deliver […]

Read more..

Co-Formulate strengthens relationship with Proveca to develop multiple paediatric formulations

Nottingham, UK, 10 January 2017 Agreement builds on recent success developing the formulation for Proveca’s approved paediatric medicine Sialanar® Co-Formulate Limited (‘Co-Formulate’), a division of Quotient Clinical (‘Quotient’), a leading provider of early stage drug development services, today announced it has been contracted by Proveca Ltd. (Proveca) to perform paediatric formulation development work on several […]

Read more..
Back to top

Archives

Subscribe